Lucius LuciMava Mavacamten 2.5mg

Product Information

• Product name: LuciMava Mavacamten 2.5mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Mavacamten
• Current strength: 2.5mg
• SKU: LU-ITEM-75
• Site category: cardiomyopathy, other cancer

Product Summary

LuciMava Mavacamten 2.5mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Mavacamten is the active ingredient used for this product page. Public prescribing information for Mavacamten was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation. Excess myosin actin cross-bridge formation and dysregulation of the super-relaxed state are mechanistic hallmarks of HCM. Mavacamten shifts the overall myosin population towards an energy-sparing, recruitable, super-relaxed state.

Reference Indications

Mavacamten ® is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. Mavacamten is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.

Reference Dosage and Administration

Recommended dose is 15 mg orally once daily. takes weeks to reach steady-state drug levels and therapeutic effects, and genetic variation in metabolism and drug interactions can cause large differences in exposure .

With this 2.5mg product, that corresponds to 6 x 2.5mg tablets when that reference dose is clinically appropriate.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

WARNING: RISK OF HEART FAILURE Mavacamten reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction . Echocardiogram assessments of LVEF are required prior to and during treatment with Mavacamten. Initiation of Mavacamten in patients with LVEF <55% is not recommended. Interrupt Mavacamten if LVEF is <50% at any visit or if the patient experiences heart failure symptoms or worsening clinical status .

Common Adverse Reactions and Monitoring

The safety of Mavacamten was evaluated in EXPLORER-HCM, a Phase 3, double-blind, randomized, placebo-controlled trial . Mavacamten-treated patients had a median duration of exposure of 30 weeks (range: 2-40 weeks). Syncope (0.8%) was the only adverse drug reaction leading to discontinuation in patients receiving Mavacamten. The safety of Mavacamten in patients was further evaluated in VALOR-HCM, a Phase 3, double-blind, randomized, placebo-controlled trial . Mavacamten-treated patients had a median duration of exposure of 17 weeks (range: 3-19 weeks). Effects on Systolic Function In the EXPLORER-HCM trial, mean (SD) resting LVEF was 74% at baseline in both treatment groups.

Drug Interactions and Special Populations

Weak to moderate CYP2C19 inhibitors and moderate to strong CYP3A4 inhibitors : May increase risk of heart failure. If initiating an inhibitor, Mavacamten dose reduction and additional monitoring are required. ( 2.2 , 7.1 ) Negative inotropes : Close medical supervision and LVEF monitoring is recommended if a negative inotrope is initiated, or the dose of a negative inotrope is increased. Avoid certain combinations of negative inotropes. Inducers and inhibitors of CYP2C19 and moderate to strong inhibitors or inducers of CYP3A4 may affect the exposures of mavacamten . Prevention or Management Concomitant use with a strong CYP2C19 inhibitor is contraindicated.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: CAMZYOS public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.